ECMO for severe ARDS: systematic review and individual patient data meta analysis
To assess the effect of venovenous extracorporeal membrane oxygenation (ECMO) compared to conventional management in patients with severe acute respiratory distress syndrome (ARDS) We conducted a systematic review and individual patient data meta analysis of randomised controlled trials (RCTs) performed after Jan 1, 2000 comparing ECMO to conventional management in patients with severe ARDS. The primary outcome was 90 day mortality. Primary analysis was by intent to treat. We identified two RCTs (CESAR and EOLIA) and combined data from 429 patients. On day 90, 77 of the 214 (36% ECMO group and 103 of the 215 (48% control group patients had died (relative risk (RR) 0.75, 95% confidence interval (CI) 0.6 0.94; P 0.013; I2 0% In the per protocol and as treated analyses the RRs were 0.75 (95% CI 0.6 0.94) and 0.86 (95% CI 0.68 1.09) respectively. Rescue ECMO was used for 36 (17% of the 215 control patients (35 in EOLIA and 1 in CESAR) The RR of 90 day treatment failure, defined as death for the ECMO group and death or crossover to ECMO for the control group was 0.65 (95% CI 0.52 0.8; I2 0% Patients randomised to ECMO had more days alive out of the ICU and without respiratory, cardiovascular, renal and neurological failure. The only significant treatment covariate interaction in subgroups was lower mortality with ECMO in patients with two or less organs failing at randomization. In this meta analysis of individual patient data in severe ARDS, 90 day mortality was significantly lowered by ECMO compared with conventional management.
Intensive Care Medicine